Tag: Spinal Muscular Atrophy

23
Dec 2019

Bionest

The SMA Market: Assessing the Unknowns

Challenges and opportunities in the field of spinal muscular atrophy, including how new disease-modifying therapies are likely to change SMA’s course over time.
2
Sep 2019

Bionest

Zolgensma Launch “On Track,” but Significant Challenges Remain

On July 18, Novartis told analysts its Zolgensma launch was “on track.” Despite the gene therapy’s $2.1 million price tag, the company states the launch is “one of the most successful launches from an access standpoint in rare diseases.” Novartis said it had reached coverage deals with more than 20 commercial insurance plans, covering approximately 40%...
17
Jun 2019

Bionest

Highlights from AAN: Part 1

The Bionest team attended the American Academy of Neurology (AAN) in early May, where we heard exciting data presented in a number of neurological conditions. Among the highlights of this year’s conference:   Transformative Success in Spinal Muscular Atrophy   Spinal muscular atrophy (SMA) was a hot topic at AAN, with presentations of positive clinical...